Xerna™ TME Panel as a predictive biomarker in lung cancer
Together with Exact Sciences and OncXerna Therapeutics, Genialis presented a retrospective study in lung cancer patients at the 2022 SITC meeting in Boston. The study established the utility of the Xerna™ TME Panel in predicting response to immune checkpoint inhibition, and concluded that it compares favourably with existing biomarkers such as the tumor mutational burden (TMB). Adding this assay to a host of other tests in Exact Sciences’ Oncomap ExTra platform now enables researchers and clinicians to make more informed clinical decisions.
The poster is available here.